GlassScriptPhysician profile
Madelyn Pellicer
NPI 1114642865
$3,429.03
in general payments reported to CMS, 2019-2025
27 companies · $1,726 in 2025
The $1,726 reported for 2025 was more than what 92% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $198 · 2023: $946 · 2024: $559 · 2025: $1,726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,230.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $409.88 | 2023-2025 | Verquvo, Winrevair, Capvaxive |
| Edwards Lifesciences Corporation | $401.00 | 2022-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Amgen INC. | $322.84 | 2023-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $321.08 | 2023-2025 | Watchman Flx, Rhythmia Mapping System, Accolade Sr |
| Pfizer INC. | $304.64 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $282.02 | 2023-2025 | |
| United Therapeutics Corporation | $209.92 | 2025 | Tyvaso |
| Actelion Pharmaceuticals US, INC. | $139.56 | 2025 | Uptravi, Opsynvi, Opsumit |
| Astrazeneca Pharmaceuticals LP | $121.18 | 2023-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.88 | 2024-2025 | Jardiance |
| Cvrx, INC. | $98.27 | 2022-2023 | Barostim Neo System |
| Scpharmaceuticals INC. | $87.10 | 2025 | |
| Medtronic, INC. | $69.57 | 2022-2025 | Micra, Linq II |
| Alnylam Pharmaceuticals INC. | $62.99 | 2025 | Amvuttra |
| Cardiva Medical, INC. | $56.39 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $55.56 | 2022-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $53.96 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $52.46 | 2023 | Eliquis, Camzyos |
| Daiichi Sankyo INC. | $48.68 | 2025 | Injectafer |
| Esperion Therapeutics, INC. | $35.00 | 2025 | Nexletol |
| Recor Medical INC | $33.01 | 2025 | Paradise Ultrasound Renal Denervation System |
| Liquidia Technologies, INC. | $32.27 | 2025 | Yutrepia |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $31.93 | 2023-2025 | Lifevest |
| Kiniksa Pharmaceuticals, LTD. | $25.02 | 2023 | Arcalyst |
| Abiomed | $21.19 | 2023 | Impella |
| Novo Nordisk INC | $19.88 | 2023 | Rybelsus, Ozempic |
| Lilly USA, LLC | $15.75 | 2025 | Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madelyn Pellicer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.